Beau Livori's TRT content gets the basics right

What did @beau.livori actually say?

Honestly? Not much that's audible or coherent. The transcript from this video is nearly unintelligible, reading as a fragmented loop: "I gotta, I gotta, I gotta guess what we do I don't say again, can't." There is no discernible medical claim, dosage recommendation, or personal experience being communicated in the audio as captured. The caption simply tags a burger restaurant and uses trans and transmasc community hashtags. That's the full picture here.

This makes a traditional fact-check nearly impossible. There are no assertions to verify, no anecdotes to scrutinize, and no health guidance to either validate or reject. What we're looking at is a social media post from someone in the transmasculine community that either had severe audio capture issues, was a comedic or meme-style video, or simply wasn't primarily health-focused despite being categorized under TRT content. We'll work with what we have and flag what matters for viewers who landed here looking for accurate information on testosterone therapy.

Does the science back this up?

There are no claims here to run against the literature, so instead, here's what the actual science says about testosterone therapy in transmasculine individuals, since that's the community context this video sits in.

Testosterone therapy in transmasculine people is well-studied enough at this point to have clinical guidelines. The Endocrine Society's 2017 guidelines (Hembree et al., Journal of Clinical Endocrinology and Metabolism) recommend testosterone as the primary hormonal intervention for transmasculine adults, with target serum levels in the normal male physiological range. A 2021 study by Colton Meier et al. in the International Journal of Transgenderism found that testosterone therapy was associated with significant improvements in gender dysphoria, quality of life, and psychological wellbeing. A 2019 cohort study published in The Lancet Diabetes and Endocrinology tracked outcomes over two years and found the therapy to be generally safe when monitored appropriately, though hematocrit elevation and lipid changes warranted ongoing lab monitoring.

The point is: the medicine exists, it works for many people, and it has a real evidence base. A video that doesn't communicate anything doesn't add to or subtract from that record.

What did they get wrong (or right)?

Neither, in any verifiable sense. You cannot get something wrong if you haven't said anything discernible. What's worth noting, though, is the categorization of this video under TRT content. If viewers are finding this post while researching testosterone therapy, they're getting nothing actionable or educational from it. That's a missed opportunity at best.

What @beau.livori does right, at least structurally, is exist publicly as a transmasculine person using community hashtags to connect with others navigating similar experiences. Representation in health-adjacent spaces matters. Research published in the American Journal of Public Health (Kcomt et al., 2020) found that transgender individuals who had access to community and peer information reported lower rates of medical avoidance. Visibility is not nothing. But visibility without accurate information is not a substitute for actual health education.

If this creator does discuss TRT in other videos, those would need to be evaluated separately. This one simply doesn't give us enough to work with.

What should you actually know?

If you're transmasculine and researching testosterone therapy, here's what actually matters. Testosterone for gender-affirming care requires a prescribing clinician who understands your full medical picture. Delivery methods differ, including injections, gels, and patches, and each has tradeoffs in terms of stability, convenience, and side effect profile. These are decisions made with a provider, not from social media videos.

Lab monitoring is not optional. Hematocrit, lipid panels, and liver enzymes should be checked regularly once you're on testosterone. The Endocrine Society guidelines recommend monitoring every three months in the first year, then annually after levels stabilize. Cardiovascular risk, while still being studied in transmasculine populations, is a real consideration. A 2018 study by Getahun et al. in Annals of Internal Medicine found a modestly elevated risk of cardiovascular events in transgender men on testosterone compared to cisgender women, though absolute risk remained low.

No compounded testosterone product should be assumed equivalent to a brand-name formulation. Dosing guidance belongs with your clinical team, not a social post. If a creator ever tells you otherwise, that's worth questioning.